TREM2 Mystery: Altered Microglia, No Effect on Plaques
In mouse models, the Alzheimer’s risk gene TREM2 affects microglial behavior but does not lead to more amyloid deposition.
80 RESULTS
Sort By:
In mouse models, the Alzheimer’s risk gene TREM2 affects microglial behavior but does not lead to more amyloid deposition.
A drug candidate for Alzheimer’s aims to make cell trafficking more efficient, reduce Aβ production.
An antibody against ApoE helps clear plaques and improves cognition in AD model mice.
Scientists report that astrocytes help neurons destroy their unwanted mitochondria.
Tau and amyloid PET tracers demonstrate potential to sharpen the diagnosis of Alzheimer’s disease and frontotemporal dementias.
Conformations of misfolded tau survive injection from one mouse to the next, a property shared by prions.
Alpha-secretase does not necessarily pick up the slack when β-secretase cleavage of amyloid precursor protein wanes, a study in primates finds. It suggests APP can be processed in other ways.
A single dose of a commonly prescribed antidepressant suppresses Aβ production in the human central nervous system.
Scientists had the good fortune to study the exceedingly rare instance of a pair of identical twins, only one of whom had Trisomy 21. It turned out that gene regulation was altered across the entire genome in the twin with Down’s syndrome.
Deep-brain stimulation of the nucleus basalis of Meynert appeared safe and tolerable for Alzheimer’s patients.
People with Alzheimer’s disease and other dementias may benefit from creative activities, but hard studies are still lacking.
A new project to identify factors that allow some carriers of pathogenic mutations to escape their genetic destinies could be applicable to neurodegenerative diseases.
X-ray crystallography reveals secrets of the glutamate receptor.
While mice sleep, neurons sprout synapses to solidify fresh skills, according to a new study. The brain also keeps amyloid-β levels low while we snooze.
An amplification-based test picks up minute amounts of prion protein in the blood of asymptomatic carriers, but researchers wonder whether regulators will want to screen the population.